Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3576 | Sequencing Wiki | 0.71 |
| drug3592 | Serology Wiki | 0.71 |
| drug2933 | Placebo Administration Wiki | 0.35 |
Navigate: Correlations HPO
There are 2 clinical trials
This study aims to examine the tolerability of high dose of leflunomide in patients with COVID-19 who are being managed in the outpatient setting.
Description: Number of subjects requiring leflunomide dose modifications
Measure: Tolerability of high dose leflunomide as measured by leflunomide dose modifications Time: 14 daysDescription: Number of subjects that discontinue leflunomide
Measure: Tolerability of high dose leflunomide as measured by discontinuation of leflunomide Time: 14 daysDescription: Number of Adverse Events observed in all subjects for the duration of the study
Measure: Tolerability of high dose leflunomide as measured by Adverse Events Time: 14 daysDescription: The number of days to reach first fever normalization (criteria for normalization: temperature < 100.4 F)
Measure: Time to defervescence as measured in days while on treatment protocol Time: 14 daysDescription: Number of days to resolve other symptoms, as assessed by a standardized questionnaire for symptom assessment
Measure: Resolution of other COVID-19 symptoms measured in days while on treatment protocol Time: 14 daysThis phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer. Leflunomide has been used since the 1990s as a treatment for rheumatoid arthritis. Experiments done with human cells that were given severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, showed that leflunomide was able to reduce the ability of the virus to make copies of itself. The coronavirus uses ribonucleic acid (RNA), a very long molecule that contains genetic information that is like a blueprint for making more copies of itself. Leflunomide inhibits the formation of RNA. The information gained from this study may help researchers to learn whether leflunomide is safe for use in treating patients with COVID-19, and whether it is potentially effective against the disease.
Description: Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study of treatment and reversibility or outcome.
Measure: Incidence of toxicity, graded according to the NCI CTCAE version 5 Time: Up to 28 days after completion of study treatmentDescription: Will be based on the assessment of dose limiting toxicity (DLT).
Measure: Maximum tolerated dose (MTD) (Phase 1) Time: During the 28-day treatment periodDescription: Defined as a >= 2-point change in clinical status from day 1 on a 7-point ordinal scale.
Measure: Clinical activity (Response)(Phase 2) Time: At day 28Description: Defined as time from start of treatment to >= 2 point change in clinical status on a 7 point ordinal scale
Measure: Time to Clinical activity (Response) Time: Up to 28 daysDescription: Defined as time from start of treatment to death from any cause
Measure: Overall Survival Time: Up to 90 daysDescription: Time from start of treatment to peripheral capillary oxygen saturation (SpO2) > 93% on room air
Measure: Oxygen Saturation improvement Time: Up to 90 daysDescription: Time from start of treatment to first negative severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) result assessed by polymerase chain reaction (PCR).
Measure: SARS-CoV-2 resolution Time: Up to 90 daysDescription: Hospitalized within first 90 days following start of treatment assessed as yes/no
Measure: Hospitalization Time: Up to 90 daysDescription: Indication as to whether or not the subject required mechanical ventilation at any time from start of treatment through 90 days post; assessed as yes/no
Measure: Mechanical Ventilation required Time: Up to 90 daysDescription: If the subject required mechanical ventilation, indicate number of days for first occurrence; measured in days.
Measure: Mechanical Ventilation duration Time: Up to 90 daysDescription: Vital status will be reported as yes/no
Measure: Vital status (alive/dead) Time: Up to 90 daysDescription: If vital status is dead, cause of death will be documented.
Measure: Vital status (cause of death) Time: Up to 90 daysDescription: Measured by PCR assay of viral ribonucleic acid (RNA) from nasopharyngeal swab.
Measure: Viral load Time: from start of treatment to 90 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports